Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004054
Abstract: Background The CD47-SIRPα pathway acts as an important myeloid cell immune checkpoint and targeting the CD47/SIRPα axis represents a promising strategy to promote antitumor immunity. Several CD47-targeting agents show encouraging early activity in clinical trials.… read more here.
Keywords: antibody br105; immune checkpoint; sirp; cd47 ... See more keywords